Evidence map›Paper›PMID 29082296›Full record

ReviewNeurology(R) neuroimmunology & neuroinflammation2017

B-cell-targeted therapies in relapsing forms of MS.

Divyanshu Dubey, Thomas Forsthuber, Eoin P Flanagan, Sean J Pittock, Olaf Stüve

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology(R) neuroimmunology & neuroinflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Pediatric Multiple Sclerosis: an Update.Current neurology and neuroscience reports · 2018
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Divyanshu DubeyDepartment of Neurology (D.B., E.P.F., S.J.P.), and Department of Laboratory Medicine and Pathology (S.J.P.), Mayo Clinic, Rochester, MN; Department of Biology (T.F.), University of Texas at San Antonio; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; Neurology Section (O.S.), VA North Texas Health Care System, Dallas VA Medical Center, TX; and Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany.
Thomas ForsthuberDepartment of Neurology (D.B., E.P.F., S.J.P.), and Department of Laboratory Medicine and Pathology (S.J.P.), Mayo Clinic, Rochester, MN; Department of Biology (T.F.), University of Texas at San Antonio; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; Neurology Section (O.S.), VA North Texas Health Care System, Dallas VA Medical Center, TX; and Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany.
Eoin P FlanaganDepartment of Neurology (D.B., E.P.F., S.J.P.), and Department of Laboratory Medicine and Pathology (S.J.P.), Mayo Clinic, Rochester, MN; Department of Biology (T.F.), University of Texas at San Antonio; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; Neurology Section (O.S.), VA North Texas Health Care System, Dallas VA Medical Center, TX; and Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany.
Sean J PittockDepartment of Neurology (D.B., E.P.F., S.J.P.), and Department of Laboratory Medicine and Pathology (S.J.P.), Mayo Clinic, Rochester, MN; Department of Biology (T.F.), University of Texas at San Antonio; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; Neurology Section (O.S.), VA North Texas Health Care System, Dallas VA Medical Center, TX; and Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany.
Olaf StüveDepartment of Neurology (D.B., E.P.F., S.J.P.), and Department of Laboratory Medicine and Pathology (S.J.P.), Mayo Clinic, Rochester, MN; Department of Biology (T.F.), University of Texas at San Antonio; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; Neurology Section (O.S.), VA North Texas Health Care System, Dallas VA Medical Center, TX; and Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical trials. Results of these trials have shown their efficacy and relatively tolerable adverse effect profiles, suggesting a favorable benefit-to-risk ratio. In this review, we discuss the pathogenic role of B cells in MS and the rationale behind the utilization of B-cell depletion as a therapeutic cellular option. We also discuss the data of clinical trials for anti-CD20 antibodies in relapsing forms of MS and existing evidence for other B-cell-directed therapeutic strategies.

Identifiers

PMID29082296
PMCPMC5656409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.